AIM:To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy(cCSC).METHODS:Patients with cCSC were classified into bevacizumab and brolucizumab group.The proport...AIM:To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy(cCSC).METHODS:Patients with cCSC were classified into bevacizumab and brolucizumab group.The proportion of complete resolution of subretinal fluid(SRF),best-corrected visual acuity(BCVA),central macular thickness(CMT),and subfoveal choroidal thickness(SFCT)were compared between the two groups.RESULTS:A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study.Twenty eyes in bevacizumab group(17 males)and 20 eyes(18 males)in brolucizumab group.Comparing the proportion of complete resolution of SRF,the brolucizumab group was statistically significantly higher than the bevacizumab group(P<0.05).In 1mo,CMT was significantly reduced in the brolucizumab group compared to the bevacizumab group(265±69 vs 319±70μm;P=0.021).However,there was no significant difference in CMT between the two groups at 2 and 3mo(P>0.05).CONCLUSION:Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.展开更多
Hepatocellular carcinoma(HCC)is the most prevalent cancer of the hepatobiliary tract and the third leading cause of cancer-related mortality worldwide.Atezolizumab and bevacizumab combination is currently considered a...Hepatocellular carcinoma(HCC)is the most prevalent cancer of the hepatobiliary tract and the third leading cause of cancer-related mortality worldwide.Atezolizumab and bevacizumab combination is currently considered among the frontline treatment modalities for advanced unresectable HCC.Most studies examining this combination were focused on evaluating its effectiveness.Despite numerous case reports documenting some side effects,there is a limited number of large-scale studies assessing these side effects.In this article,we comment on the case report by Park et al published recently,reporting a fatal intra-tumoral hemorrhage in a patient with HCC who received systemic therapy in the form of the combination of atezolizumab and bevacizumab.展开更多
BACKGROUND Gastrointestinal tumors are among the most common and deadly cancers globally,with radiotherapy and bevacizumab being key treatment strategies.Radiotherapy uses high-energy radiation to target DNA,reducing ...BACKGROUND Gastrointestinal tumors are among the most common and deadly cancers globally,with radiotherapy and bevacizumab being key treatment strategies.Radiotherapy uses high-energy radiation to target DNA,reducing tumor size and alleviating symptoms.Bevacizumab,a targeted therapy,inhibits angiogenesis and tumor growth,particularly in advanced gastrointestinal cancers.However,both treatments can cause adverse gastrointestinal effects,such as intestinal mucosal damage and perforation.While research on the risk of intestinal perforation has grown,the underlying mechanisms remain underexplored.This study aims to compare the incidence of intestinal perforation and survival rates in patients treated with radiotherapy combined with bevacizumab vs bevacizumab alone.AIM To investigate the effect of radiotherapy on the risk of intestinal perforation in patients with colon cancer treated with bevacizumab.METHODS A total of 70 patients diagnosed with gastrointestinal malignancies admitted to our hospital from January 2023 to December 2024 were selected as research subjects.According to different treatment methods,70 patients were divided into the bevacizumab only group(receiving bevacizumab treatment)and the bevacizumab+radiotherapy group(receiving radiotherapy combined with bevacizumab treatment),with 35 cases in each group.The two groups were compared in terms of clinical efficacy,incidence of intestinal perforation,serum tumor marker levels,overall survival and progression-free survival,levels of angiogenic factors,and adverse reactions.RESULTS Compared with the group treated with bevacizumab alone,the group treated with bevacizumab plus radiotherapy showed significant improvements in effective rate,overall survival,and progression-free survival(P<0.05);the probability of intestinal perforation in the bevacizumab+radiotherapy group was 13.33%,while the probability of intestinal perforation in the bevacizumab group was 0.There was a statistically significant difference in the incidence of intestinal perforation between the two groups(P=0.039).Following treatment,the levels of carbohydrate antigen(CA)125,CA199,and CA153 in patients were significantly reduced(P<0.05).CONCLUSION Radiation therapy may increase the risk of intestinal perforation in colon cancer patients receiving bevacizumab treatment.In clinical applications,the risks of combined use of radiotherapy and bevacizumab should be fully considered and personalized treatment plans should be formulated.展开更多
In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and adva...In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and advanced hepatocellular carcinoma.The triple therapy,which integrates interventional therapy,targeted therapy,and immunotherapy,has emerged as a promising research focus in the treatment of liver cancer.Consequently,it is of utmost significance to select an appropriate combination of interventional therapy,targeted therapy,and immunotherapy for patients suffering from intermediate and advanced liver cancer.展开更多
AIM:To examine effects of switching intravitreal aflibercept to bevacizumab in neovascular age-related macular degeneration(nAMD).METHODS:Data from patients treated for nAMD with anti-vascular endothelial growth facto...AIM:To examine effects of switching intravitreal aflibercept to bevacizumab in neovascular age-related macular degeneration(nAMD).METHODS:Data from patients treated for nAMD with anti-vascular endothelial growth factor(VEGF)injections atÖrebro University Hospital between January 2014 and June 2020,were extracted from the Swedish macular register(SMR).A total of 230 eyes were included in the study:116 in the study/bevacizumab switch group and 114 in the control/aflibercept group.Central retinal thickness(CRT)was measured at baseline and after 2y.Primary outcome was mean change in best corrected visual acuity(BCVA)between baseline and 2y.Secondary outcome variables included proportion of patients with a clinically significant change in BCVA[increase or decrease of≥15 Early Treatment Diabetic Retinopathy Study(ETDRS)letters],mean change in CRT,number of anti-VEGF injections,number of visits assessing disease activity and number of visits with active disease.RESULTS:The mean difference in BCVA between baseline and 2y was 1.13±14.47 ETDRS letters in the bevacizumab switch group and 1.81±13.01 ETDRS letters in the aflibercept group.The lower bound of the 95%confidence interval of the difference in BCVA was-4.25,indicating non-inferiority within a 5 ETDRS letter limit.No significant differences in mean change of CRT between baseline and 2y were detected(study-185.9±167.0 versus control-149.4±193.1μm,P=0.127).The distribution of clinically significant improvement(P=0.598)or worsening(P=0.508)of BCVA during follow-up did not show statistically significant differences between groups.The number of anti-VEGF injections administered(study 12.76±2.20 versus control 13.10±4.20,P=0.442),the number of visits assessing disease activity(P=0.301),and the number of visits with active disease(P=0.065)did not show differences between subjects receiving bevacizumab and aflibercept treatment.No significant differences were detected in baseline characteristics between the study and control groups,including age,BCVA,CRT,neovascular membrane type or location,duration of symptoms or prior cataract surgery.CONCLUSION:Switching to off-label bevacizumab in patients responding to initial aflibercept treatment is noninferior to continued aflibercept treatment with respect to change in visual acuity at 2y.Switching anti-VEGF from aflibercept to bevacizumab may be a viable option in clinical settings with limited resources.展开更多
无论在发展中国家还是在发达国家,早产儿视网膜病变(retinopathy of prematurity,ROP)都是小儿致盲的主要原因。预防ROP失明的关键在于及时发现阈值或阈值前病变,并在"时间窗"内进行冷凝或光凝治疗,尽管如此,仍有部分患眼会...无论在发展中国家还是在发达国家,早产儿视网膜病变(retinopathy of prematurity,ROP)都是小儿致盲的主要原因。预防ROP失明的关键在于及时发现阈值或阈值前病变,并在"时间窗"内进行冷凝或光凝治疗,尽管如此,仍有部分患眼会发展到4期、5期ROP。4期、5期ROP术后解剖结构和视力的预后都不容乐观。因此,ROP的治疗方法仍有待进一步发展,近年来有报道用玻璃体腔注射Bevacizumab治疗ROP,取得了一定的疗效。本文就Bevacizumab在ROP治疗中的应用进展进行扼要综述。展开更多
基金Supported by research fund from Chosun University Hospital,2022.
文摘AIM:To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy(cCSC).METHODS:Patients with cCSC were classified into bevacizumab and brolucizumab group.The proportion of complete resolution of subretinal fluid(SRF),best-corrected visual acuity(BCVA),central macular thickness(CMT),and subfoveal choroidal thickness(SFCT)were compared between the two groups.RESULTS:A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study.Twenty eyes in bevacizumab group(17 males)and 20 eyes(18 males)in brolucizumab group.Comparing the proportion of complete resolution of SRF,the brolucizumab group was statistically significantly higher than the bevacizumab group(P<0.05).In 1mo,CMT was significantly reduced in the brolucizumab group compared to the bevacizumab group(265±69 vs 319±70μm;P=0.021).However,there was no significant difference in CMT between the two groups at 2 and 3mo(P>0.05).CONCLUSION:Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.
文摘Hepatocellular carcinoma(HCC)is the most prevalent cancer of the hepatobiliary tract and the third leading cause of cancer-related mortality worldwide.Atezolizumab and bevacizumab combination is currently considered among the frontline treatment modalities for advanced unresectable HCC.Most studies examining this combination were focused on evaluating its effectiveness.Despite numerous case reports documenting some side effects,there is a limited number of large-scale studies assessing these side effects.In this article,we comment on the case report by Park et al published recently,reporting a fatal intra-tumoral hemorrhage in a patient with HCC who received systemic therapy in the form of the combination of atezolizumab and bevacizumab.
文摘BACKGROUND Gastrointestinal tumors are among the most common and deadly cancers globally,with radiotherapy and bevacizumab being key treatment strategies.Radiotherapy uses high-energy radiation to target DNA,reducing tumor size and alleviating symptoms.Bevacizumab,a targeted therapy,inhibits angiogenesis and tumor growth,particularly in advanced gastrointestinal cancers.However,both treatments can cause adverse gastrointestinal effects,such as intestinal mucosal damage and perforation.While research on the risk of intestinal perforation has grown,the underlying mechanisms remain underexplored.This study aims to compare the incidence of intestinal perforation and survival rates in patients treated with radiotherapy combined with bevacizumab vs bevacizumab alone.AIM To investigate the effect of radiotherapy on the risk of intestinal perforation in patients with colon cancer treated with bevacizumab.METHODS A total of 70 patients diagnosed with gastrointestinal malignancies admitted to our hospital from January 2023 to December 2024 were selected as research subjects.According to different treatment methods,70 patients were divided into the bevacizumab only group(receiving bevacizumab treatment)and the bevacizumab+radiotherapy group(receiving radiotherapy combined with bevacizumab treatment),with 35 cases in each group.The two groups were compared in terms of clinical efficacy,incidence of intestinal perforation,serum tumor marker levels,overall survival and progression-free survival,levels of angiogenic factors,and adverse reactions.RESULTS Compared with the group treated with bevacizumab alone,the group treated with bevacizumab plus radiotherapy showed significant improvements in effective rate,overall survival,and progression-free survival(P<0.05);the probability of intestinal perforation in the bevacizumab+radiotherapy group was 13.33%,while the probability of intestinal perforation in the bevacizumab group was 0.There was a statistically significant difference in the incidence of intestinal perforation between the two groups(P=0.039).Following treatment,the levels of carbohydrate antigen(CA)125,CA199,and CA153 in patients were significantly reduced(P<0.05).CONCLUSION Radiation therapy may increase the risk of intestinal perforation in colon cancer patients receiving bevacizumab treatment.In clinical applications,the risks of combined use of radiotherapy and bevacizumab should be fully considered and personalized treatment plans should be formulated.
文摘In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and advanced hepatocellular carcinoma.The triple therapy,which integrates interventional therapy,targeted therapy,and immunotherapy,has emerged as a promising research focus in the treatment of liver cancer.Consequently,it is of utmost significance to select an appropriate combination of interventional therapy,targeted therapy,and immunotherapy for patients suffering from intermediate and advanced liver cancer.
文摘AIM:To examine effects of switching intravitreal aflibercept to bevacizumab in neovascular age-related macular degeneration(nAMD).METHODS:Data from patients treated for nAMD with anti-vascular endothelial growth factor(VEGF)injections atÖrebro University Hospital between January 2014 and June 2020,were extracted from the Swedish macular register(SMR).A total of 230 eyes were included in the study:116 in the study/bevacizumab switch group and 114 in the control/aflibercept group.Central retinal thickness(CRT)was measured at baseline and after 2y.Primary outcome was mean change in best corrected visual acuity(BCVA)between baseline and 2y.Secondary outcome variables included proportion of patients with a clinically significant change in BCVA[increase or decrease of≥15 Early Treatment Diabetic Retinopathy Study(ETDRS)letters],mean change in CRT,number of anti-VEGF injections,number of visits assessing disease activity and number of visits with active disease.RESULTS:The mean difference in BCVA between baseline and 2y was 1.13±14.47 ETDRS letters in the bevacizumab switch group and 1.81±13.01 ETDRS letters in the aflibercept group.The lower bound of the 95%confidence interval of the difference in BCVA was-4.25,indicating non-inferiority within a 5 ETDRS letter limit.No significant differences in mean change of CRT between baseline and 2y were detected(study-185.9±167.0 versus control-149.4±193.1μm,P=0.127).The distribution of clinically significant improvement(P=0.598)or worsening(P=0.508)of BCVA during follow-up did not show statistically significant differences between groups.The number of anti-VEGF injections administered(study 12.76±2.20 versus control 13.10±4.20,P=0.442),the number of visits assessing disease activity(P=0.301),and the number of visits with active disease(P=0.065)did not show differences between subjects receiving bevacizumab and aflibercept treatment.No significant differences were detected in baseline characteristics between the study and control groups,including age,BCVA,CRT,neovascular membrane type or location,duration of symptoms or prior cataract surgery.CONCLUSION:Switching to off-label bevacizumab in patients responding to initial aflibercept treatment is noninferior to continued aflibercept treatment with respect to change in visual acuity at 2y.Switching anti-VEGF from aflibercept to bevacizumab may be a viable option in clinical settings with limited resources.
文摘无论在发展中国家还是在发达国家,早产儿视网膜病变(retinopathy of prematurity,ROP)都是小儿致盲的主要原因。预防ROP失明的关键在于及时发现阈值或阈值前病变,并在"时间窗"内进行冷凝或光凝治疗,尽管如此,仍有部分患眼会发展到4期、5期ROP。4期、5期ROP术后解剖结构和视力的预后都不容乐观。因此,ROP的治疗方法仍有待进一步发展,近年来有报道用玻璃体腔注射Bevacizumab治疗ROP,取得了一定的疗效。本文就Bevacizumab在ROP治疗中的应用进展进行扼要综述。
